End of March, end of June take your pick but for sure it is coming. Those let go on the Cardiovascular side in August were let go a week prior to the sales meeting in Dallas. Oh by the way, you have been laid off and would you please cancel your travel reservations to Dallas. Then bring over a neuro sales team, replacing the displaced reps, to sell Brilinta. Made sense and then let 700 more go in December Pascal has been and will be a very significant factor in the demise of AZ. When he took over it was well known that the 2015/2016 timeframe would see a huge patent cliff with billions in revenue lost. He could have made better strategic decisions and acquisitions of products, to maintain or even grow the company, until various compounds made it through the pipeline. The minions heads will be severed, while he and others will make million dollar bonuses despite the ship sinking. Sure they were counting on Brilinta and multiple indications. However, much like the diabetes products in the BMS acquisition, Brilinta is a johnny come lately to the market. BID doseing, dyspnea, doj investigation, poor leadership during initial launch, generic Plavix, effient going generic this year. It was doomed once the stroke trial failed. There has been more DTC ads in the last 2 weeks for Brilinta, then there had been during the period from launch until end of 2016. Oh yes Frenchie bought a fish oil capsule, they claim had manufacturing issues. Come on with dozens of fish oil capsules otc , AZ can't figure out how to keep capsules from leaking? Truth be known, if you look it up there was a patent infringement lawsuit. Az probably after purchasing it, realized they would either loose the suit or be forced to pay royalties. Movantix was a hit and so was the ZSpharma acquisition. Frenchie will only be around another year. Again, long enough to make a few more millions. His failures are catching up quicker than he can bail the water from the bottom of the boat. He will not come close to hitting his marks without a miracle breakthrough drug or three. Shareholders will realize if they haven't already, that when Pfizer came knocking they should have filled their pockets with the offer. That boat will never return to the dock